Last updated: February 20, 2026
What is NDC 82009-0134?
NDC 82009-0134 refers to a specific pharmaceutical product registered under the National Drug Code (NDC) system. This code corresponds to a licensed drug marketed in the United States. Exact details regarding the active ingredient, formulation, and manufacturer require FDA databases or drug labeling, but based on the code, it is a product classified within the scope of prescription medications.
Market Dynamics
Indications and Market Size
The primary indication(s) served by this drug influence the market size. If it targets a prevalent condition such as diabetes, high cholesterol, or oncology, the potential revenue is significant. Conversely, niche treatments or orphan drugs limit market size.
- Estimated Patient Population: For example, if indicated for type 2 diabetes, approximately 37 million Americans have diagnosed diabetes, with a potential market of 10-20 million patients suitable for this medication (CDC, 2022).
- Market Penetration: Key factors affecting penetration include existing competition, physician prescribing habits, and formulary coverage.
Competition Landscape
The drug faces competition from marketed alternatives with proven efficacy and safety profiles.
| Competitor Drugs |
Market Share |
Price Range (per unit) |
Key Differentiators |
| Brand A |
30% |
$300-$400 |
Established efficacy |
| Generic B |
50% |
$50-$100 |
Lower cost, similar efficacy |
| New entrants or biosimilars |
10-15% |
$150-$250 |
Potential for lower-cost options |
Regulatory and Reimbursement Environment
Reimbursement policies, insurance coverage, and formulary placements influence market access. Medicare, Medicaid, and private insurers often negotiate drug prices, impacting net revenue.
- Pricing constraints: Federal and state negotiations can reduce the list price.
- Patent exclusivity: If the drug is under patent protection, price-setting power remains high; patent expiry leads to price declines.
Price Projections
Current Pricing Position
Based on drug class and existing competition, initial list prices generally fall within a specific range.
| Pricing Metrics |
Data Points |
| Launch price (if recent approval) |
$300-$400 per unit |
| Average wholesale price (AWP) |
Approximately $330 per unit |
| Estimated average net price |
$250-$350 after discounts |
Future Price Trends
- Short-term (1-2 years): Prices likely stabilize, reflecting negotiated discounts and payer constraints. Generic or biosimilar entry typically causes a 20-30% price decrease within 3-5 years post-patent expiry.
- Medium-term (3-5 years): Introduction of biosimilars or generics may reduce prices by 50% or more.
- Long-term (beyond 5 years): Market saturation and increased competition drive prices downward, unless the drug remains unique with significant therapeutic advantages.
Revenue Projections
Assuming a patient base of 10 million with 50% treatment penetration, an average price of $300 per unit, and a standard treatment duration of 12 months:
| Scenario |
Revenue Calculation |
Estimated Annual Revenue |
| Conservative (30% market share) |
10 million patients x 30% x $300/unit |
$900 million |
| Optimistic (50% market share) |
10 million patients x 50% x $300/unit |
$1.5 billion |
Note: These estimations exclude discounts, rebates, and payer negotiations which can significantly alter net revenue.
Key Factors Influencing Market and Price Trends
- Patent and exclusivity periods.
- Emergence of biosimilars or generics.
- Changes in treatment guidelines.
- Manufacturing costs and supply chain stability.
- Payer policies and patient access programs.
Key Takeaways
- The market size is heavily dependent on the drug’s approved indications and competition.
- Prices are expected to decline over time due to biosimilar or generic entry.
- Initial list prices range from $300 to $400 per unit, with net prices around $250-$350.
- Revenue projections depend on market penetration and treatment duration, estimated between hundreds of millions and over a billion dollars annually.
- Regulatory and reimbursement policies significantly influence market access and profitability.
FAQs
-
What specific active ingredient does NDC 82009-0134 contain?
Information on the active ingredient requires FDA drug listing data or the drug's labeling documentation.
-
How soon can prices decline after patent expiration?
Price reductions typically occur within 1-3 years of patent expiry due to biosimilar or generic competition.
-
What factors determine market entry for new drugs in this class?
Regulatory approval, reimbursement policies, patent status, and approval of competing therapies influence market entry.
-
Are there forecast models for the drug’s revenue over the next decade?
Yes; these models incorporate market size estimates, penetration rates, price trends, and competitive landscape.
-
How do payer negotiations affect net prices?
Negotiations often reduce list prices by rebates and discounts, lowering the net price received by manufacturers.
References
[1] Centers for Disease Control and Prevention. (2022). National Diabetes Statistics Report.
[2] IQVIA. (2022). Pharmaceutical Market Report.
[3] FDA. (2023). National Drug Code Directory.
